ZARZA We are Zarza, the prestigious firm behind major projects in information technology.
Listen "Emerging Therapeutic Developments in Non-Targetable Metastatic NSCLC "
Episode Synopsis
CME credits: 1.25
Valid until: 31-07-2026
Claim your CME credit at https://reachmd.com/programs/cme/emerging-therapeutic-developments-in-non-targetable-metastatic-nsclc/36153/
The rapid pace of therapeutic advances in lung cancer (LC) demands continual learning and adaptation from oncology clinicians. With new agents, indications, and biomarker-driven strategies emerging at an unprecedented rate, staying current is essential to delivering optimal care—but also increasingly challenging. This microlearning-based activity is designed to distill key clinical topics in a unique and digestible manner that can be easily integrated into a busy clinician’s schedule. This activity will enable providers to engage in succinct, faculty-driven discussions addressing current gaps related to the diagnosis and individualized management of patients with early and advanced non-small cell lung cancer (NSCLC) as well as limited- and extensive-stage small cell lung cancer (SCLC).
Valid until: 31-07-2026
Claim your CME credit at https://reachmd.com/programs/cme/emerging-therapeutic-developments-in-non-targetable-metastatic-nsclc/36153/
The rapid pace of therapeutic advances in lung cancer (LC) demands continual learning and adaptation from oncology clinicians. With new agents, indications, and biomarker-driven strategies emerging at an unprecedented rate, staying current is essential to delivering optimal care—but also increasingly challenging. This microlearning-based activity is designed to distill key clinical topics in a unique and digestible manner that can be easily integrated into a busy clinician’s schedule. This activity will enable providers to engage in succinct, faculty-driven discussions addressing current gaps related to the diagnosis and individualized management of patients with early and advanced non-small cell lung cancer (NSCLC) as well as limited- and extensive-stage small cell lung cancer (SCLC).
In God we trust